Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial

John D. Steeves, Daniel P. Lammertse, John L K Kramer, Naomi Kleitman, Sukhvinder Kalsi-Ryan, Linda Jones, Armin Curt, Andrew R. Blight, Kimberly D Anderson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Effective treatment after cervical spinal cord injury (SCI) is imperative as so many activities of daily living (ADLs) are dependent on functional recovery of arm and hand actions. We focus on defining and comparing neurological and functional endpoints that might be used during acute or subacute Phase 2 clinical trials involving subjects with cervical sensorimotor complete SCI (ASIA Impairment Scale [AIS-A]). For the purposes of this review, the trial would examine the effects of a pharmaceutical small molecule, drug, biologic, or cell transplant on spinal tissue. Thus, neurological improvement is the intended consequence and is most directly measured by assessing neurological impairment (eg, motor aspects of the International Standards Neurological Classification of Spinal Cord Injury [ISNCSCI]). However, changes in neurological function, even if statistically significant, may not be associated with a clear functional impact (ie, a meaningful improvement in individual activity, such as independent self-care ADLs). The challenge is to measure improvement as precisely as possible (change in impairment), but to define a clinically meaningful response in the context of functional improvement (impact on activity limitations). The principal comparisons focused on elements of the ISNCSCI assessment, including upper extremity motor score and motor level. Personal activity capabilities were also examined at various time points. The data suggest that an improvement of 2 or more motor levels after cervical sensorimotor complete SCI may be a clinically meaningful endpoint threshold that could be used for acute and subacute Phase 2 trials with subjects having sensorimotor complete cervical SCI.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalTopics in Spinal Cord Injury Rehabilitation
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Spinal Cord Injuries
Outcome Assessment (Health Care)
Clinical Trials
Activities of Daily Living
Internationality
Self Care
Upper Extremity
Pharmaceutical Preparations
Arm
Hand
Transplants

Keywords

  • activity
  • function
  • impairment
  • ISNCSCI
  • neurology
  • responder analysis
  • SCIM

ASJC Scopus subject areas

  • Clinical Neurology
  • Rehabilitation
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Steeves, J. D., Lammertse, D. P., Kramer, J. L. K., Kleitman, N., Kalsi-Ryan, S., Jones, L., ... Anderson, K. D. (2012). Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial. Topics in Spinal Cord Injury Rehabilitation, 18(1), 1-14. https://doi.org/10.1310/sci1801-1

Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial. / Steeves, John D.; Lammertse, Daniel P.; Kramer, John L K; Kleitman, Naomi; Kalsi-Ryan, Sukhvinder; Jones, Linda; Curt, Armin; Blight, Andrew R.; Anderson, Kimberly D.

In: Topics in Spinal Cord Injury Rehabilitation, Vol. 18, No. 1, 01.01.2012, p. 1-14.

Research output: Contribution to journalArticle

Steeves, JD, Lammertse, DP, Kramer, JLK, Kleitman, N, Kalsi-Ryan, S, Jones, L, Curt, A, Blight, AR & Anderson, KD 2012, 'Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial', Topics in Spinal Cord Injury Rehabilitation, vol. 18, no. 1, pp. 1-14. https://doi.org/10.1310/sci1801-1
Steeves, John D. ; Lammertse, Daniel P. ; Kramer, John L K ; Kleitman, Naomi ; Kalsi-Ryan, Sukhvinder ; Jones, Linda ; Curt, Armin ; Blight, Andrew R. ; Anderson, Kimberly D. / Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial. In: Topics in Spinal Cord Injury Rehabilitation. 2012 ; Vol. 18, No. 1. pp. 1-14.
@article{2c23929a062a4f2b8e3e7ace411a1f3d,
title = "Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial",
abstract = "Effective treatment after cervical spinal cord injury (SCI) is imperative as so many activities of daily living (ADLs) are dependent on functional recovery of arm and hand actions. We focus on defining and comparing neurological and functional endpoints that might be used during acute or subacute Phase 2 clinical trials involving subjects with cervical sensorimotor complete SCI (ASIA Impairment Scale [AIS-A]). For the purposes of this review, the trial would examine the effects of a pharmaceutical small molecule, drug, biologic, or cell transplant on spinal tissue. Thus, neurological improvement is the intended consequence and is most directly measured by assessing neurological impairment (eg, motor aspects of the International Standards Neurological Classification of Spinal Cord Injury [ISNCSCI]). However, changes in neurological function, even if statistically significant, may not be associated with a clear functional impact (ie, a meaningful improvement in individual activity, such as independent self-care ADLs). The challenge is to measure improvement as precisely as possible (change in impairment), but to define a clinically meaningful response in the context of functional improvement (impact on activity limitations). The principal comparisons focused on elements of the ISNCSCI assessment, including upper extremity motor score and motor level. Personal activity capabilities were also examined at various time points. The data suggest that an improvement of 2 or more motor levels after cervical sensorimotor complete SCI may be a clinically meaningful endpoint threshold that could be used for acute and subacute Phase 2 trials with subjects having sensorimotor complete cervical SCI.",
keywords = "activity, function, impairment, ISNCSCI, neurology, responder analysis, SCIM",
author = "Steeves, {John D.} and Lammertse, {Daniel P.} and Kramer, {John L K} and Naomi Kleitman and Sukhvinder Kalsi-Ryan and Linda Jones and Armin Curt and Blight, {Andrew R.} and Anderson, {Kimberly D}",
year = "2012",
month = "1",
day = "1",
doi = "10.1310/sci1801-1",
language = "English",
volume = "18",
pages = "1--14",
journal = "Topics in Spinal Cord Injury Rehabilitation",
issn = "1082-0744",
publisher = "Thomas Land Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial

AU - Steeves, John D.

AU - Lammertse, Daniel P.

AU - Kramer, John L K

AU - Kleitman, Naomi

AU - Kalsi-Ryan, Sukhvinder

AU - Jones, Linda

AU - Curt, Armin

AU - Blight, Andrew R.

AU - Anderson, Kimberly D

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Effective treatment after cervical spinal cord injury (SCI) is imperative as so many activities of daily living (ADLs) are dependent on functional recovery of arm and hand actions. We focus on defining and comparing neurological and functional endpoints that might be used during acute or subacute Phase 2 clinical trials involving subjects with cervical sensorimotor complete SCI (ASIA Impairment Scale [AIS-A]). For the purposes of this review, the trial would examine the effects of a pharmaceutical small molecule, drug, biologic, or cell transplant on spinal tissue. Thus, neurological improvement is the intended consequence and is most directly measured by assessing neurological impairment (eg, motor aspects of the International Standards Neurological Classification of Spinal Cord Injury [ISNCSCI]). However, changes in neurological function, even if statistically significant, may not be associated with a clear functional impact (ie, a meaningful improvement in individual activity, such as independent self-care ADLs). The challenge is to measure improvement as precisely as possible (change in impairment), but to define a clinically meaningful response in the context of functional improvement (impact on activity limitations). The principal comparisons focused on elements of the ISNCSCI assessment, including upper extremity motor score and motor level. Personal activity capabilities were also examined at various time points. The data suggest that an improvement of 2 or more motor levels after cervical sensorimotor complete SCI may be a clinically meaningful endpoint threshold that could be used for acute and subacute Phase 2 trials with subjects having sensorimotor complete cervical SCI.

AB - Effective treatment after cervical spinal cord injury (SCI) is imperative as so many activities of daily living (ADLs) are dependent on functional recovery of arm and hand actions. We focus on defining and comparing neurological and functional endpoints that might be used during acute or subacute Phase 2 clinical trials involving subjects with cervical sensorimotor complete SCI (ASIA Impairment Scale [AIS-A]). For the purposes of this review, the trial would examine the effects of a pharmaceutical small molecule, drug, biologic, or cell transplant on spinal tissue. Thus, neurological improvement is the intended consequence and is most directly measured by assessing neurological impairment (eg, motor aspects of the International Standards Neurological Classification of Spinal Cord Injury [ISNCSCI]). However, changes in neurological function, even if statistically significant, may not be associated with a clear functional impact (ie, a meaningful improvement in individual activity, such as independent self-care ADLs). The challenge is to measure improvement as precisely as possible (change in impairment), but to define a clinically meaningful response in the context of functional improvement (impact on activity limitations). The principal comparisons focused on elements of the ISNCSCI assessment, including upper extremity motor score and motor level. Personal activity capabilities were also examined at various time points. The data suggest that an improvement of 2 or more motor levels after cervical sensorimotor complete SCI may be a clinically meaningful endpoint threshold that could be used for acute and subacute Phase 2 trials with subjects having sensorimotor complete cervical SCI.

KW - activity

KW - function

KW - impairment

KW - ISNCSCI

KW - neurology

KW - responder analysis

KW - SCIM

UR - http://www.scopus.com/inward/record.url?scp=84856620027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856620027&partnerID=8YFLogxK

U2 - 10.1310/sci1801-1

DO - 10.1310/sci1801-1

M3 - Article

AN - SCOPUS:84856620027

VL - 18

SP - 1

EP - 14

JO - Topics in Spinal Cord Injury Rehabilitation

JF - Topics in Spinal Cord Injury Rehabilitation

SN - 1082-0744

IS - 1

ER -